Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07006792 · ClinicalTrials.gov registry record · Phase 4
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
A Phase 4 study of Atopic Dermatitis, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT07006792: Recruiting Phase 4 study of Atopic Dermatitis, sponsored by Eli Lilly and Company.
NCT07006792 is a Phase 4 study of Atopic Dermatitis that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 200 participants, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07006792, a Phase 4 study of Atopic Dermatitis, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to measure how well taking lebrikizumab alone works for participants with fewer places on the body with eczema (atopic dermatitis), but these places may be very itchy. Participation in this study will last up to approximately 38 weeks (9 and a half months) including 24 weeks (6 months) of treatment.
Primary Outcome
The primary endpoint will be a composite endpoint as defined by achieving either EASI-75 or Pruritus NRS≥4-point Reduction from Baseline.
Conditions Studied
Interventions
- DRUG Lebrikizumab
Study Locations (20)
Florida
- Suncoast Research Associates - Doral
- Encore Medical Research - Hollywood
- Solutions Through Advanced Research - Jacksonville
- Life Arc Research Centers - Miami - Miami
- MCR Research - Miami
- Health Clinical Research - Miami
- Deluxe Health Center - Miami Lakes
- Renstar Medical Research - Ocala
- Leading Edge Dermatology - Plantation
- Research Institute of the Southeast - West Palm Beach
California
- California Dermatology & Clinical Research Institute - Encinitas
- First OC Dermatology Research Inc - Fountain Valley
- Dermatology Research Associates - Los Angeles
- NorCal Clinical Research - Rocklin
Arizona
- Research Solutions of Arizona - Litchfield Park
- Alliance Dermatology and Mohs Center - Phoenix
Alabama
- Total Skin & Beauty Dermatology Center, PC DBA Total Dermatology - Birmingham
Georgia
- Dermatology Affiliates Research Institute - Atlanta
Illinois
- DeNova Research - Chicago
Indiana
- Southern Indiana Clinical Research Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-06-16 |
| Est. Completion | 2026-09 |
| Phase | Phase 4 |
What NCT07006792 shows while recruiting
NCT07006792 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which Lebrikizumab is the first listed.
NCT07006792 names 20 study sites across 7 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT07006792 about?
NCT07006792 is a clinical study titled "A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden". The purpose of this study is to measure how well taking lebrikizumab alone works for participants with fewer places on the body with eczema (atopic dermatitis), but these places may be very itchy. Participation in this study will last up to approximately 38 weeks (9 and a half months) including 24 ...
What is the current status of trial NCT07006792?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2025-06-16. Estimated completion is 2026-09.
What conditions does trial NCT07006792 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT07006792?
The interventions under investigation include: Lebrikizumab (DRUG).
Who is sponsoring clinical trial NCT07006792?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07006792 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07006792's enrollment target sits among peer trials
200 56th of 150 higher than 89 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
RECRUITING · Phase 4
-
Molecular Signatures of Cutaneous Dupilumab Response
RECRUITING · Phase 4
-
Ethnic Differences in Mechanisms of Action of Dupilumab
RECRUITING · Phase 4
-
Dupixent and Narrowband UVB for Atopic Dermatitis
RECRUITING · Phase 4
-
Lebrikizumab in Moderate-to-severe Atopic Dermatitis
RECRUITING · Phase 4
-
Dupilumab De-escalation in Pediatric Atopic Dermatitis
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
- NCT00568490 · 200 participants
Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI